ITM

the world's leading supplier of non-carrier-added Lutetium-177, with a Lu-177 manufacturing collaboration with the Institut Laue-Langevin dating to 2009 and a fresh 2026 supply agreement with Radiopharm Theranostics.

Country
Germany
isotope-supply eu
Coverage
CNEUUS
therapeutics-platforms
Regulatorsfdaemanmpa

Verifiable facts

FactValueSource
Funding€188 million venture round in 2024 (2024-06-01)globenewswire.com
Production siteNOVA facility in Neufahrn, Germany (world's largest Lu-177 production site) (2024-01-04)itm-radiopharma.com
Production siteIAZ facility in Garching, Germany (2022-10-13)biospace.com
Revenue$380 million in 2024 (2024-12-31) medium confidencecompworth.com · privco.com
Regulatory approvalRadioactive Material Handling License (RAM License) for NOVA facility (2024-01-04)ans.org · itm-radiopharma.com
CertificationGMP standards compliant (EndolucinBeta) (2023-01-01)itm-radiopharma.com
CapacityMultiplied capacity with new IAZ production line; NOVA facility capacity can serve up to several hundred thousand patients annually (2022-10-13)biospace.com

Independent sources: ans.org · biospace.com · compworth.com · globenewswire.com · itm-radiopharma.com · privco.com

Technologies
NameClusterRisk
Radiopharmaceuticals & theranosticstherapeutics-platformsHigh

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.